Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for business professionals · Monday, April 6, 2020 · 513,939,990 Articles · 3+ Million Readers

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Allakos (ALLK) Investors with Losses to Contact Its Attorneys: Application Deadline Approaching

/EIN News/ -- SAN FRANCISCO, March 25, 2020 (GLOBE NEWSWIRE) -- Hagens Berman urges Allakos Inc. (NASDAQ: ALLK) investors who have suffered significant losses to submit their losses now. A securities fraud class action has been filed against the Company and certain investors may have valuable claims. 

Class Period: Aug. 5, 2019 - Dec. 17, 2019
Lead Plaintiff Deadline: May 11, 2020
Sign Up: www.hbsslaw.com/investor-fraud/ALLK
Contact An Attorney Now: ALLK@hbsslaw.com
                                             844-916-0895

Allakos (ALLK) Securities Class Action:

The complaint alleges Defendants misled investors about the Company’s Phase 2 clinical trial (the “ENIGMA Trial”) for its flagship AK002 drug intended to treat patients with certain stomach diseases. Specifically, Defendants misrepresented and concealed that: (1) the ENIGMA Trial was poorly designed and not well-controlled; (2) Allakos had cherry-picked timeframes to engineer results for the ENIGMA Trial; (3) Allakos used superficial endpoints in the ENIGMA Trial relative to FDA guidance; (4) Allakos inaccurately reported the number of adverse incidents that occurred during the ENIGMA Trial; and (5) the Company failed to report other key data from the ENIGMA Trial.

According to the complaint, investors began to learn the truth on Dec. 18, 2019, when Seligman Investments published a scathing report entitled, “A Suspect Biotech with a Phase 2 Farce, Incredulous Trial Investigators, and Warning Signs of Potential Fraud,” identifying several concerns with the ENIGMA Trial. Among other things, Seligman’s 215-page report concluded that the ENIGMA Trial results “are compromised by 1) glaring omissions, 2) cherry-picked measures, and 3) statistical gimmicks and obfuscation.” On this news, Allakos shares declined $13.25, or about 10%, on Dec. 18, 2019, wiping out over $1 billion in market capitalization.

“We’re focused on investors’ losses and whether Allakos misrepresented the conditions and results of its ENIGMA Trial,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you purchased shares of Allakos and suffered significant losses, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Allakos should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email ALLK@hbsslaw.com.

About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:
Reed Kathrein, 844-916-0895

Primary Logo

Powered by EIN News
Distribution channels: Consumer Goods, Law


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release